$IPHA News

Innate Pharma S.A. 2026 Q1 - Results - Earnings Call Presentation

Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call Transcript

Innate Pharma Advances Lacutamab Phase 3 Trial And IPH4502 ADC Amid €25.4M Cash Runway Through Q3 2026

HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target

Innate Pharma FY EPS $(0.64) Beats $(0.65) Estimate, Sales $10.483M Beat $7.230M Estimate

BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025

Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

Innate Pharma Releases Its 2026 Financial Calendar

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

Innate Pharma to Present at Jefferies Global Healthcare Conference

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Innate Pharma Reports €56.4M Cash And €2.3M Nine-Month Revenue As Lacutamab Advances Toward TELLOMAK-3 Phase 3 Initiation In 2026

Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

Innate Pharma Gains FDA Clearance To Launch TELLOMAK 3 Phase 3 Trial Of Lacutamab In Sézary Syndrome And Mycosis Fungoides

Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

HC Wainwright & Co. Upgrades Innate Pharma to Buy, Announces $5 Price Target

BTIG Reiterates Buy on Innate Pharma, Maintains $8 Price Target